Market Place
Sourcing Support
Enforcement Report - Week of December 4, 2024
04 Dec 2024 //
FDA
Enforcement Report - Week of September 13, 2023
13 Sep 2023 //
FDA
Enforcement Report - Week of March 15, 2023
15 Mar 2023 //
FDA
Initiator Pharma obtains approval to begin trial for pain-reducing effects
27 Nov 2021 //
CLINICALTRIALSARENA
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA
19 Dec 2019 //
PR NEWSWIRE
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)
18 Dec 2019 //
PR NEWSWIRE
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent
03 Dec 2019 //
GLOBE NEWSWIRE
Kindler`s Centrexion restarts IPO bid to fund phase 3 pain trial
20 Sep 2019 //
FIERCE BIOTECH
Grunenthal Acquires Averitas Pharma, Establishes Commercial Footprint in the US
14 Nov 2018 //
BIOSPACE
Grünenthal Acquires Global Rights for Qutenza®
05 Nov 2018 //
PR NEWSWIRE
Enforcement Report - Week of May 30, 2018
29 May 2018 //
FDA
New FDA Report Cites 22 Drugs That Passed PhII But Crashed and Burned in PhIII
21 Jan 2017 //
BIOSPACE
Grünenthal to Commercialise Astellas`s Dermal Patch Qutenza
14 Dec 2016 //
PHARMABIZ
Anvisa suspends lot of dermatological cream Moment
26 Apr 2016 //
ANVISA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.